OBJECTIVE: This study sought to evaluate the @entity137 and curative effect of @entity2600 plus @entity900 neoadjuvant chemotherapy (NACT) for stage @entity3847 , IIa2, and IIb @entity5 @entity1 . METHODS: A total of 219 @entity1 were randomly assigned to two groups: 109 @entity1 were treated with 1-2 cycles of chemotherapy (NACT group), and 110 @entity1 in the control group were treated directly with surgery (DS group). @entity1 in the NACT group were randomly assigned to two groups: 50 @entity1 were treated with @entity2600 plus @entity900 followed by surgery (IP group), and 59 @entity1 were treated with @entity1311 plus @entity900 followed by surgery (TP group). @entity1 with pathological recurrence risk factors received post-operative radiotherapy. RESULTS: Survival analysis revealed no significant difference in disease-free survival (DFS) or @entity1349 ( @entity1349 ) between the NACT and DS groups. Analysis of clinicopathologic factors showed that the lymphovascular space invasion (LVSI) and deep stromal invasion rates were significantly lower in the NACT group. Grade 3/4 @entity1398 and grade 3/4 @entity294 were both higher in the IP group than in the TP group. DFS and @entity1349 were similar in the IP and TP groups. Univariate analysis showed that LVSI was the only factor associated with DFS. CONCLUSION: NACT did not improve @entity1349 but did reduce the number of @entity1 who received post-operative radiotherapy. NACT consisting of @entity2600 plus @entity900 for @entity5 showed similar efficacy and higher @entity137 compared with the use of @entity1311 plus @entity900 , although the @entity137 was tolerable.

The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced XXXX : A randomized multicenter study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity3847 :: ('23542', 'Gene') :: ['Ib2'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']
